Drug Information

Drug General Information
Drug ID
D0H3HV
Former ID
DIB003912
Drug Name
AP-1030
Synonyms
AP-1102; AP-1130; MS-05; Combined MC1/MC4 receptor agonists, Action Pharma; Melanocortin-1/-4 receptor agonists, ActionPharma; Melanocortin-1/melanocortin-4 receptor agonists, Action Pharma
Indication Metabolic disorders [ICD9: 270-279; ICD10:E70-E89] Phase 1/2 [522018], [538812]
Company
Action Pharma A/S
Structure
Download
2D MOL

3D MOL
Canonical SMILES
C1CN([C@@H](C1)C(=O)N[C@H](C(=O)N)C(C)C)C(=O)[C@@H](NC(<br />=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]<br />(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC<br />(=O)[C@@H](N)CO)CO)[C@@H](C)CC)[C@@H](C)CC)CO)Cc1c[nH]c<br />n1)Cc1ccccc1)CCCNC(=N)N)Cc1c[nH]c2c1cccc2)CCCCN
Target and Pathway
Target(s) Melanocyte stimulating hormone receptor Target Info Modulator [1572591]
Melanocortin-4 receptor Target Info Modulator [1572591]
KEGG Pathway Neuroactive ligand-receptor interaction
Melanogenesishsa04080:Neuroactive ligand-receptor interaction
Pathway Interaction Database Syndecan-3-mediated signaling events
Reactome Peptide ligand-binding receptors
G alpha (s) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
G alpha (s) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Peptide GPCRs
GPCR ligand binding
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
GPCR downstream signaling
References
Ref 522018ClinicalTrials.gov (NCT00464958) One Year Extension Study To Protocol C2/5/TZ:MS-05. U.S. National Institutes of Health.
Ref 538812(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1322).
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.